DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DMAC Hot Sheet
Join SI Premium – FREE
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).
For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- First Hawaiian (FHB) Misses Q3 EPS by 7c
- DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
